The Surgical and Oncological Outcomes of Radical Hysterectomy for Early Cervical Cancer
Cervical cancer is the second most common cancer among women in incidence and mortality in India. Early cervical cancer is treated primarily by radical hysterectomy where the ovaries may be preserved. The aim of this study was to report the complications and survival outcomes of radical hysterectomy.
All 61 patients who underwent modified radical or radical hysterectomy for early-stage cervical cancer in the Department of Obstetrics and Gynaecology at a tertiary-level teaching hospital, between 2001 and 2010, were included. Patients who received neoadjuvant treatments were excluded. Clinical details were obtained from discharge summaries and medical records, both paper and electronic.
The mean age of the patients was 53 years (SD 10) with a range of 33–77 years. Most tumours were squamous cell carcinomas (78%) and stage IB1 (72%). Most tumours (84%) were smaller than 4 cm in size. There were no perioperative deaths. The most common complications were urinary tract infections in 29% and voiding dysfunction in 23%. Injuries occurred in seven patients (11.5%): three ureters, three iliac vessels and one bowel. Blood transfusion rate was 31%. High risk factors were present in 14 patients (23%) and at least two intermediate risk factors in eight patients (13%). Adjuvant radiation therapy was given in these 22 patients. Seven patients were lost to follow-up. Recurrence occurred in ten patients and death occurred in eight patients, of whom disease was documented in seven. The recurrence-free survival was 79% at 3 years and 74% at 5 years. The overall survival was 89% at 3 years, 84% at 5 years and 79% at 10 years.
Radical hysterectomy can cure the majority of patients with early cervical cancer. Patients with stages IB2 and IIA have significantly more recurrence and less survival.
KeywordsCervical cancer Radical hysterectomy Complications Survival
Research Funds from CMC Hospital, Vellore, are gratefully acknowledged
Compliance with Ethical Standards
Conflict of interest
None of the authors have any conflict of interest.
This study was approved by our institutional review board. Since this was a retrospective chart review, informed consent from patients was waived.
- 1.Bray FB, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;0:1–31.Google Scholar
- 3.Herrero R, Murillo R. Cervical Cancer. In: Thun MJ, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D, editors. Cancer epidemiology and prevention. 4th ed. New York: Oxford University Press; 2018. p. 925–46.Google Scholar
- 4.Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012. Cancer incidence and mortality worldwide: IARC Cancer Base No. 11. Lyon. IARC 2013.Google Scholar
- 7.Akkus YB, Onal C, Erbay G, Cem GO, Karadeli E, Reyhan M, Koc Z. Prognostic value of ADCmean and SUVmax of the primary tumour in cervical cancer patients treated with definitive chemoradiotherapy. J Obstet Gynaecol. 2018;24:1–7.Google Scholar
- 14.Ramirez PT, Frumovitz M, Pareja R et al. Phase III randomised trial of laparoscopic or robotic versus abdominal radical hysterectomy in patients with early-stage cervical cancer: LACC trial. 2018 Society of Gynecological Oncology Annual Meeting on women’s Cancer. LBA1. Presented Mar 26th 2018.Google Scholar